Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Abera Bioscience Chlamydia vaccine
- Development stage
- Preclinical
- Lead developer
- Abera Bioscience
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Abera Bioscience is developing an intranasal vaccine candidate for the prevention of *Chlamydia trachomatis* sexually transmitted infections. The vaccine utilizes the company's proprietary Outer Membrane Vesicle (OMV) platform, specifically Salmonella-derived OMVs that are decorated with *Chlamydia trachomatis* antigens, including MOMP-derived CTH522 and HtrA. This modular platform allows for the display of heterologous antigens while providing inherent adjuvant properties. Administered intranasally to induce mucosal immunity, the vaccine has demonstrated the ability to elicit both systemic and local immune responses in preclinical mouse models, including humoral responses in vaginal compartments and cellular responses (CD4+ Th1 and Th17). It is currently in early exploratory/preclinical development.
- Other names
- OMV-based Chlamydia Vaccine
02
Targets
CtHtrA (Periplasmic serine endoprotease HtrA)MOMP (Major outer membrane protein)
Beyond the preview
Go deeper on Abera Bioscience Chlamydia vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abera Bioscience Chlamydia vaccine.